Size | Price | Stock | Qty |
---|---|---|---|
250mg |
|
||
Other Sizes |
|
Targets |
SARS-CoV-2[1]
|
---|---|
ln Vitro |
For the purification of vaccines, propiolactone (β-propiolactone) can be employed. Following the collection of cells using low-speed centrifugation, Propiolactone (1:1000 v:v) was used to chemically inactivate SARS-CoV. SARS-CoV was incubated with propiolactone for a whole day at 4°C. To hydrolyze any remaining propiolactone, a second incubation is carried out at room temperature. and the vaccine's concentration. after BPL deactivation. To precipitate the inactivated virus, a combination of polyethylene glycol and sodium chloride (PEG-NaCl) was applied. following vaccination and concentration. A combination of polyethylene glycol and sodium chloride (PEG-NaCl) is used to inactivate the virus and precipitate it once propiolactone has been rendered inactive. As a final bacteriostatic agent, 1:10000 v:v propiolactone was applied. In Vero cells, the propiolactone-inactivated virus becomes less contagious [1].
|
ln Vivo |
The influenza A virus was inactivated with propiolactone (β-propiolactone) and injected intramuscularly into mice at a dose of approximately 25 mg total protein. Young BALB/c mice treated with propiolactone inactivation are not fatally affected by SARS. Even while the virus continued to grow in the mice's respiratory system, by day five it had disappeared. After the mice were infected, 1.5 μg of total hemagglutinin protein were produced as a result of propiolactone treatment, which was negative [1].
|
References |
[1]. Roberts A, et al. Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine. Viral Immunol. 2010 Oct;23(5):509-19
[2]. Kulkarni R, et al. Anti-SARS-CoV-2 IgG antibody response among Indian COVID-19 patients using β-propiolactone-inactivated, whole virus-based indirect ELISA. J Virol Methods. 2021 Jan;287:113996. |
Molecular Formula |
C3H4O2
|
---|---|
Molecular Weight |
72.06
|
CAS # |
57-57-8
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O1C(C([H])([H])C1([H])[H])=O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 13.8773 mL | 69.3866 mL | 138.7732 mL | |
5 mM | 2.7755 mL | 13.8773 mL | 27.7546 mL | |
10 mM | 1.3877 mL | 6.9387 mL | 13.8773 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.